Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Alanine transaminase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    642 result(s) found for: Alanine transaminase. Displaying page 1 of 33.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-004322-24 Sponsor Protocol Number: ARN-509-003 Start Date*: 2013-08-27
    Sponsor Name:Aragon Pharmaceuticals, Inc
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer
    Medical condition: Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Trial now transitioned) FI (Completed) SE (Completed) NL (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) NO (Completed) DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) HU (Completed) CZ (Trial now transitioned) SK (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-003230-15 Sponsor Protocol Number: BEV-EFF Start Date*: 2006-10-17
    Sponsor Name:University Clinic Internal Medicine I
    Full Title: Phase I/II study investigating increasing doses of bevacizumab in patients with malignant effusion
    Medical condition: Malignant effusion in cancer patients requiring frequent centesis, at least two within six weeks
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019110-24 Sponsor Protocol Number: CZOL446HDE43T Start Date*: 2010-12-27
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: A PHASE 2, SINGLE-CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF ZOLEDRONATE IN SUBJECTS WITH EROSIVE HAND OSTEOARTHRITIS
    Medical condition: Erosive hand osteoarthritis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10019115 Hand osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005472-13 Sponsor Protocol Number: Ply-5013 Start Date*: 2008-09-19
    Sponsor Name:Plymouth Hospitals NHS Trust
    Full Title: Phase II Single Agent Lenalidomide (Revlimid) in Relapsed / Refratory Mantle Cell Lymphoma.
    Medical condition: Relapsed / Refractory Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026800 Mantle cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002510-11 Sponsor Protocol Number: CYC202-04-13 Start Date*: 2005-09-26
    Sponsor Name:Cyclacel Ltd
    Full Title: Protocol for the Extended Use of CYC202 for Patients who have previously been enrolled in a Clinical Trial with CYC202
    Medical condition: Stage IIIB/IV Non-small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-005068-26 Sponsor Protocol Number: H6Q-MC-JCAR(d) Start Date*: 2005-06-17
    Sponsor Name:Eli Lilly and Company limited
    Full Title: A Phase 2 Study of Oral Enzastaurin HCl in Patients with Metastatic Colorectal Cancer
    Medical condition: metastatic colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-012437-30 Sponsor Protocol Number: BUS‐2009/01 Start Date*: 2010-06-17
    Sponsor Name:Skånes University Hospital
    Full Title: Clofarabine based remission induction followed by haploidentical stem cell transplantation in children with refractory hematological malignancies
    Medical condition: Therapy resitant leukemia in children and young adults
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004149-16 Sponsor Protocol Number: H3E-ES-S085 Start Date*: 2005-02-16
    Sponsor Name:Lilly S.A.
    Full Title: Phase 1/2 Study of Biweekly ALIMTA plus Cisplatin in patients with Locally Advanced, non-Resectable or Metastatic Urothelial Cancer
    Medical condition: Locally Advanced, non-Resectable or Metastatic Urothelial Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-001149-14 Sponsor Protocol Number: A6181034 Start Date*: 2004-09-27
    Sponsor Name:PFIZER
    Full Title: A Phase 3, Randomized Study of SU011248 versus Interferon-a as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma.
    Medical condition: metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10050513 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000035-25 Sponsor Protocol Number: ET-B-028-06 Start Date*: 2007-07-13
    Sponsor Name:Pharma Mar, S.A.
    Full Title: A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (Yondelis®) in Patients with Localized Myxoid / Round Cell Liposarcoma
    Medical condition: Localized myxoid / round cell liposarcoma previously untreated with chemotherapy or radiation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024630 Liposarcoma non-metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001762-13 Sponsor Protocol Number: 747-401 Start Date*: 2018-08-01
    Sponsor Name:Intercept Pharmaceuticals, Inc.
    Full Title: A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients with Primary Biliary Cholangitis and Moderate to Severe Hepa...
    Medical condition: Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) BE (Completed) HU (Prematurely Ended) EE (Prematurely Ended) LT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004619-23 Sponsor Protocol Number: CC-10004-PSA-001 Start Date*: 2007-02-05
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two dose regimens of CC-10004 in subjects with active psoriatic arthritis
    Medical condition: Active psoriatic arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004667-61 Sponsor Protocol Number: SUITE - CUOG-TE 05 Start Date*: 2007-02-22
    Sponsor Name:Universitätsklinikum Hamburg-Eppendorf
    Full Title: Prospective open-labeled non randomized Phase-II study of SU011248 (Sunitinib) in male patients with relapsed or cisplatin-refractory germ cell cancer - A CUOG/GTCSG cooperative phase II study
    Medical condition: germ cell cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061378 Testicular germ cell cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002854-19 Sponsor Protocol Number: S58827 Start Date*: 2017-08-03
    Sponsor Name:UZ Leuven
    Full Title: Neoadjuvant degarelix +/- apalutamide (ARN-509) followed by radical prostatectomy for intermediate and high-risk prostate cancer: a randomized, placebo-controlled trial.
    Medical condition: Prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004011-39 Sponsor Protocol Number: CACZ885T2301 Start Date*: 2018-01-31
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/...
    Medical condition: stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GR (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) NO (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended) SI (Prematurely Ended) IS (Completed) IE (Prematurely Ended) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2008-002158-40 Sponsor Protocol Number: A6181120 Start Date*: 2008-07-22
    Sponsor Name:Pfizer S.A.
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB PLUS PREDNISONE VERSUS PREDNISONE IN PATIENTS WITH PROGRESSIVE METASTATIC HORMONE-REFRACTORY PROSTATE CANCER AFTER FAILURE OF A D...
    Medical condition: (mHRPC) after failure of a docetaxel-based chemotherapy regimen Cáncer de próstata resistente a las hormonas metastático (CPRHm) tras el fracaso de una pauta de quimioterapia basada en el docetaxel
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Prematurely Ended) GB (Prematurely Ended) SE (Completed) DE (Prematurely Ended) PT (Prematurely Ended) SK (Prematurely Ended) DK (Prematurely Ended) CZ (Prematurely Ended) FR (Completed) FI (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000028-34 Sponsor Protocol Number: H3E-MC-JMDB Start Date*: 2004-07-06
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A randomised Phase 3 Trial of ALIMTA and Cisplatin versus GEMZAR and Cisplatin in Patients with locally advanced or metastatic Non-Small-Cell Lung Cancer
    Medical condition: Locally advanced or metastatic Non-Small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-023355-29 Sponsor Protocol Number: PO1425 Start Date*: 2011-05-18
    Sponsor Name:Papworth Hospital NHS Foundation Trust
    Full Title: Tyrosine kinase Inhibitors in DysplAsia of Lung epithelium Study 1
    Medical condition: High grade dysplasia of the bronchoepithelium
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10057004 Bronchial dysplasia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-008676-13 Sponsor Protocol Number: CCR3164 Start Date*: 2009-08-04
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: A Phase II Study Of Sunitinib And Low Dose Metronomic Cyclophosphamide In Advanced Renal Cell Cancer
    Medical condition: Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-003736-22 Sponsor Protocol Number: M17-142 Start Date*: 2020-07-08
    Sponsor Name:AbbVie Inc.
    Full Title: Bioavailability and Food Effect of Experimental Glecaprevir + Pibrentasvir Pediatric Formulation in Healthy Adult Subjects
    Medical condition: Hepatitis C virus (HCV) infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 19:19:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA